Literature DB >> 8558128

Assessment of antigenicity and genetic variation of glycoprotein B of murine cytomegalovirus.

J Xu1, P A Lyons, M D Carter, T W Booth, N J Davis-Poynter, G R Shellam, A A Scalzo.   

Abstract

An analysis of linear antibody-binding sites of the glycoprotein B (gB) molecule of murine cytomegalovirus (MCMV) and of genetic variation within these regions was performed. To achieve this, a series of overlapping fragments spanning the entire coding sequence of the gB gene of the K181 strain of MCMV was expressed in E. coli as fusion proteins with glutathione S-transferase (GST) using the pGEX expression system. Four antibody-binding regions were mapped to locations spanning amino acid residues 17-79 (BS), 155-278 (BE2), 809-926 (SS) and 347-508 (BB and EE), based on reactivity in Western blot analysis of GST-gB fusion proteins with murine polyclonal antiserum raised against MCMV. Only the antibody-binding region BE2 (155-278) elicited an antiserum that exhibited complement-dependent neutralizing activity, and immunization of mice with the fusion protein BE2 led to moderate but significant reductions in the level of MCMV replication in the spleen. Polyclonal antisera raised against the GST-gB fusion proteins detected purified virion proteins of 105 kDa (anti-BS and anti-BE2) and 52 kDa (anti-SS) and are therefore likely to recognize the N-terminal and C-terminal portions of the gB molecule, respectively. The antibody-binding region within amino acid residues 17-79 was found to be MCMV strain-specific, whereas antibody-binding regions within residues 155-278 and 809-926 were found to be conserved among MCMV field isolates. Comparative sequence analysis of the corresponding regions of MCMV gB revealed a level and extent of sequence of sequence heterogeneity consistent with these findings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558128     DOI: 10.1099/0022-1317-77-1-49

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.

Authors:  Christopher S Morello; Ming Ye; Deborah H Spector
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells.

Authors:  Valentina Voigt; Catherine A Forbes; Joanne N Tonkin; Mariapia A Degli-Esposti; Hamish R C Smith; Wayne M Yokoyama; Anthony A Scalzo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

4.  Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected mice.

Authors:  Laurent Gillet; Michael B Gill; Susanna Colaco; Christopher M Smith; Philip G Stevenson
Journal:  J Gen Virol       Date:  2006-12       Impact factor: 3.891

5.  Glycoprotein B switches conformation during murid herpesvirus 4 entry.

Authors:  Laurent Gillet; Susanna Colaco; Philip G Stevenson
Journal:  J Gen Virol       Date:  2008-06       Impact factor: 3.891

Review 6.  MHC class I immune evasion in MCMV infection.

Authors:  Carmen M Doom; Ann B Hill
Journal:  Med Microbiol Immunol       Date:  2008-03-11       Impact factor: 3.402

7.  Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B.

Authors:  Laurent Gillet; Philip G Stevenson
Journal:  EMBO J       Date:  2007-11-22       Impact factor: 11.598

8.  The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization.

Authors:  Laurent Gillet; Janet S May; Susanna Colaco; Philip G Stevenson
Journal:  PLoS One       Date:  2007-08-08       Impact factor: 3.240

9.  Post-exposure vaccination improves gammaherpesvirus neutralization.

Authors:  Laurent Gillet; Janet S May; Philip G Stevenson
Journal:  PLoS One       Date:  2007-09-19       Impact factor: 3.240

10.  Ly49C-dependent control of MCMV Infection by NK cells is cis-regulated by MHC Class I molecules.

Authors:  Catherine A Forbes; Anthony A Scalzo; Mariapia A Degli-Esposti; Jerome D Coudert
Journal:  PLoS Pathog       Date:  2014-05-29       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.